This article has been updated with comments from Qiagen and Promega.

NEW YORK (GenomeWeb) – Thermo Fisher Scientific announced today that it is the first firm to meet draft guidelines being developed by the International Organization for Standardization to minimize the risk of human DNA contamination in forensics products.

The firm's Warrington, UK manufacturing site was confirmed to be in adherence to the draft standard by a forensic quality and validation expert, the firm said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.